Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTL
Bruns Ingmar received 9,727 Zentalis Pharmaceuticals, Inc. shares as an award (Form 4)
Traded Sep 30, 2026 · Filed Oct 1, 2026
On Sep 30, 2026, Bruns Ingmar (Chief Medical Officer) received 9,727 Zentalis Pharmaceuticals, Inc. shares as an award at US$2.18 for US$21,205, leaving 43,059 shares. Filed Oct 1, 2026 (Form 4).
- Awarded
- 9,727 shares
- Price
- US$2.18
- Value
- US$21,205
- Holding after
- 43,059 shares
- Trading plan
- No
- Role
- Chief Medical Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Common Stock | Award | 9,727 | US$2.18 | 43,059 | Direct |
Source
Related
- Zentalis Pharmaceuticals, Inc.
- Bruns Ingmar
- Zentalis Pharmaceuticals, Inc. shareholders
- Form 4 · Walters William Thurman · Aug 19, 2026
- Schedule 13G/A · Walters Group · Aug 19, 2026
- Schedule 13G/A · Barclays PLC · Aug 13, 2026
- Schedule 13G · BlackRock, Inc. · Jul 30, 2026
- Form 4 · Johnson David Michael · Jun 18, 2026